Cynvenio Biosystems, Inc., a developer of high performance cell isolation technology for biomedical research and novel cancer diagnostics, today announced that Amit Munshi and Simon Raab, Ph.D. have joined its board of directors.
Mr. Munshi, a leading Southern California biopharma executive, is president and CEO of Percivia, LLC (www.percivia.com), a venture formed to develop therapeutics using the PER.C6® human cell line. He is also the co-founder and former Chief Business Officer of Kythera Biopharmaceuticals Inc. (www.kytherabiopharma.com), a venture-backed company focused on novel prescription products in the field of aesthetic medicine. Under Mr. Munshi’s leadership, Kythera successfully commercialized technology licensed from academia and large bio-pharmaceutical companies, and recently completed a $373 million licensing transaction with a division of Bayer Healthcare AG. Prior to co-founding Kythera, Mr. Munshi served as the General Manager of Amgen’s [NASDAQ:AMGN] $700 million European Nephrology Business based in Switzerland. He has also held positions in sales, marketing, managed care, and product licensing during tenures at Astra Merck and IOLAB Corporation, a Johnson & Johnson Company.
Dr. Simon Raab, a pioneer in computer-aided coordinate measurement systems, co-founded FARO Technologies, Inc. [NASDAQ:FARO] in 1981, and served as its president and CEO until 2005, and continues to serve as the company’s chairman. During his tenure, FARO grew from a technology start-up into a publicly traded company with over $200 million in revenue and tens of thousands of customers globally including Boeing, DaimlerChrysler, Airbus, General Motors, Johnson Controls, Lockheed Martin, Siemens, Caterpillar and Honda.
Dr. Raab is the chairman of Novim (www.novim.org), a think tank formed to apply the techniques and methodologies developed at the Kavli Institute for Theoretical Physics at UC Santa Barbara to address major interrelated issues such as climate change, renewable energy, and fresh water. Dr. Raab also serves as Director of TrueVision Systems, Inc. (www.truevisionsys.com), of Santa Barbara, California, a leader in digital 3D visualization and guidance systems for ophthalmic microsurgery.
Dr. Raab holds more than 80 US and foreign patents in the fields of 3D coordinate measuring systems, biomaterials, and medical diagnostics. He holds a Ph.D. in Mechanical Engineering from McGill University, Montreal, Canada, a Masters of Engineering Physics from Cornell University and a Bachelor of Science in Physics with a minor in Biophysics from the University of Waterloo, Canada.
“We are very pleased to welcome Mr. Munshi and Dr. Raab to the Board of Directors,” said André de Fusco, Cynvenio’s chief executive officer. “These are exceptional individuals with proven track records of success. Their experience will be invaluable as Cynvenio enters its commercial growth stage.”
“Both gentlemen bring extensive contacts in the biotech and medical device industries and their deep expertise in strategic transactions and technology licensing will be a valuable asset and complement to our current board,” said Fred Gluck, Cynvenio’s co-founder and chairman of the board.
About Cynvenio Biosystems, Inc.
Cynvenio Biosystems, Inc. is a privately held company focused on the development of high performance cell isolation technology for biomedical research and novel cancer diagnostics. The company’s rare cell detection and mutational profiling methodology for personalized medicine applications includes newly-developed blood-based tests for the early detection of disease and the selection of individual therapeutic solutions. Cynvenio is based in Westlake Village, California. Find more information at www.cynvenio.com.